Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

S Boyer

Showing results (291-300 of 428) with videos related to

Pageof 43
Sort By:
Investigative Ophthalmology & Visual Science|April 16, 2016
Drusen Volume as a Predictor of Disease Progression in Patients With Late Age-Related Macular Degeneration in the Fellow EyeNizar Saleh Abdelfattah, Hongyang Zhang, David S Boyer, et al.
Transplantation Proceedings|November 20, 1997
Plasma amino acid study during discordant liver xenoperfusionM Adham, C Vianey-Saban, C Ducerf, et al.
Frontiers in Cellular Neuroscience|September 10, 2025
Retinal progenitor cells (jCell) for retinitis pigmentosaJing Yang, Baruch D Kuppermann, David Liao, et al.
The American Review of Respiratory Disease|June 1, 1974
Hypersensitivity lung disease in the turkey raising industryR S Boyer, L E Klock, C D Schmidt, et al.
Ophthalmic Surgery, Lasers & Imaging Retina|October 14, 2022
The Safety and Biological Activity of OTT166, a Novel Topical Selective Integrin Inhibitor for the Treatment of Diabetic Eye Disease: A Phase 1b StudyDavid S Boyer, Peter K Kaiser, George N Magrath, et al.
American Journal of Infection Control|July 16, 2015
Prolonged delay for controlling KPC-2-producing Klebsiella pneumoniae outbreak: the role of clinical managementT Delory, E Seringe, G Antoniotti, et al.
Ophthalmology|February 3, 2016
Intravitreal Aflibercept Injection in Diabetic Macular Edema Patients with and without Prior Anti-Vascular Endothelial Growth Factor Treatment: Outcomes from the Phase 3 ProgramDiana V Do, Quan Dong Nguyen, Robert Vitti, et al.
Ophthalmology. Retina|May 7, 2026
Effects of Time From Diagnosis to Treatment and Baseline Vision on Retinal Vein Occlusion Outcomes in Aflibercept 2 mg Phase 3 TrialsSumit Sharma, Dilsher S Dhoot, Dilraj S Grewal, et al.
Journal of Vitreoretinal Diseases|August 16, 2024
Real-World Outcomes of the 0.19 mg Fluocinolone Acetonide Intravitreal Implant for Diabetic Macular EdemaChristine Morozova, Lucas L Humayun, Jonathan Kasper, et al.
The New England Journal of Medicine|October 6, 2006
Ranibizumab for neovascular age-related macular degenerationPhilip J Rosenfeld, David M Brown, Jeffrey S Heier, et al.
Pageof 43

Showing results (291-300 of 428) with videos related to

Sort By:
Pageof 43
Investigative Ophthalmology & Visual Science|April 16, 2016
Drusen Volume as a Predictor of Disease Progression in Patients With Late Age-Related Macular Degeneration in the Fellow EyeNizar Saleh Abdelfattah, Hongyang Zhang, David S Boyer, et al.
Transplantation Proceedings|November 20, 1997
Plasma amino acid study during discordant liver xenoperfusionM Adham, C Vianey-Saban, C Ducerf, et al.
Frontiers in Cellular Neuroscience|September 10, 2025
Retinal progenitor cells (jCell) for retinitis pigmentosaJing Yang, Baruch D Kuppermann, David Liao, et al.
The American Review of Respiratory Disease|June 1, 1974
Hypersensitivity lung disease in the turkey raising industryR S Boyer, L E Klock, C D Schmidt, et al.
Ophthalmic Surgery, Lasers & Imaging Retina|October 14, 2022
The Safety and Biological Activity of OTT166, a Novel Topical Selective Integrin Inhibitor for the Treatment of Diabetic Eye Disease: A Phase 1b StudyDavid S Boyer, Peter K Kaiser, George N Magrath, et al.
American Journal of Infection Control|July 16, 2015
Prolonged delay for controlling KPC-2-producing Klebsiella pneumoniae outbreak: the role of clinical managementT Delory, E Seringe, G Antoniotti, et al.
Ophthalmology|February 3, 2016
Intravitreal Aflibercept Injection in Diabetic Macular Edema Patients with and without Prior Anti-Vascular Endothelial Growth Factor Treatment: Outcomes from the Phase 3 ProgramDiana V Do, Quan Dong Nguyen, Robert Vitti, et al.
Ophthalmology. Retina|May 7, 2026
Effects of Time From Diagnosis to Treatment and Baseline Vision on Retinal Vein Occlusion Outcomes in Aflibercept 2 mg Phase 3 TrialsSumit Sharma, Dilsher S Dhoot, Dilraj S Grewal, et al.
Journal of Vitreoretinal Diseases|August 16, 2024
Real-World Outcomes of the 0.19 mg Fluocinolone Acetonide Intravitreal Implant for Diabetic Macular EdemaChristine Morozova, Lucas L Humayun, Jonathan Kasper, et al.
The New England Journal of Medicine|October 6, 2006
Ranibizumab for neovascular age-related macular degenerationPhilip J Rosenfeld, David M Brown, Jeffrey S Heier, et al.
Pageof 43